Physician profile
Eugene Kwon
NPI 1154199628
$6,414.87
in general payments reported to CMS, 2019-2025
23 companies · $3,630 in 2025
The $3,630 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,785 · 2025: $3,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,296 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,295.85 |
| Education | $119.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,826.13 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $754.46 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $669.21 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $572.77 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $470.50 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $454.78 | 2024-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $309.11 | 2024-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $211.19 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $182.94 | 2024-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $158.99 | 2025 | Jornay Pm |
| Alkermes, INC. | $147.06 | 2024-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $141.84 | 2024-2025 | Cobenfy |
| Livanova USA, INC. | $112.33 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $81.87 | 2024-2025 | Xelstrym |
| Tris Pharma INC | $76.95 | 2024-2025 | Dyanavel Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $68.82 | 2025 | Auvelity |
| Neos Therapeutics, LP | $43.21 | 2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Lundbeck LLC | $30.76 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $27.31 | 2024 | |
| Almatica Pharma LLC | $24.22 | 2024 | Loreev Xr |
| Corium, LLC | $20.71 | 2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $16.16 | 2024 | Quviviq |
| Lilly USA, LLC | $13.55 | 2024 | Amyvid, Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.